Cefixime Capsules

Cefixime is a third-generation oral cephalosporin that kills bacteria by inhibiting bacterial cell wall synthesis. It is stable to most β-lactamases, and many strains producing penicillinase and cephalosporinase are still sensitive to this product. Cefixime has good antibacterial effects in vitro and in vivo against Gram-positive cocci such as pneumococci, Streptococcus pyogenes, and Gram-negative bacilli such as Haemophilus influenzae (including enzyme-producing strains), Moraxella catarrhalis (including enzyme-producing strains), Escherichia coli, Proteus mirabilis, and Neisseria gonorrhoeae (including enzyme-producing strains). Cefixime also has antibacterial activity against Streptococcus pneumoniae, Parainfluenzae, Proteus vulgaris, Klebsiella pneumoniae, Pasteurella multocida, Providencia, Salmonella, Shigella, Serratia marcescens, Citrobacter heteromorphis, and Citrobacter malonate, but its clinical effectiveness has not yet been established. This product has poor antibacterial effect on Staphylococcus, and has no antibacterial effect on Pseudomonas aeruginosa, Enterobacter, Bacteroides fragilis, Clostridium, etc.

This drug is a newly developed cephalosporin antibiotic with a vinyl group on the 3rd side chain of 7-aminocephalosporanic acid and a carboxymethoxyimino group on the 7th side chain. The chemical name of cefixime is (6R,7R)-7-[(2)-2-(2-amino-4-thiazolyl)-2-(carboxymethyloxime)-acetylamino-8-oxo-3-vinyl-5-thioxo-1-azabicyclo[4,2]

This product is a hard capsule. After removing the capsule, the contents are white or light yellow powder.

This product is suitable for pharyngitis, tonsillitis, acute bronchitis and acute exacerbation of chronic bronchitis, otitis media, urinary tract infection, simple gonorrhea (cervicitis or urethritis) caused by sensitive bacteria.

Adults take 400 mg per day, and children take 8 mg/kg per day, either orally in a single dose or in two divided doses. Children weighing ≥50 kg or aged ≥12 years should use the adult dose. A single dose of 400 mg is appropriate for the treatment of simple gonorrhea. A single dose of 400 mg is appropriate for the treatment of simple gonorrhea. Patients with renal insufficiency whose creatinine clearance (CCr) is 21-60 ml/min and undergoing hemodialysis should be given 50% of the standard dose, i.e., 300 mg per day; patients with CCr ≤20 ml/min and undergoing peritoneal dialysis should be given 50% of the standard dose, i.e., 200 mg per day.

Most of the adverse reactions of cefixime are short-lived and mild. The most common are gastrointestinal reactions, including diarrhea (16%), increased bowel movement (6%), abdominal pain (3%), nausea (7%), indigestion (3%), and abdominal distension (4%); adverse reactions with an incidence rate of less than 2% include rash, urticaria, drug fever, itching, headache, and dizziness. Laboratory abnormalities include transient increases in ALT, AST, ALP, LDH, bilirubin, BUN, and Cr, transient decreases in platelet and white blood cell counts and eosinophilia, and positive direct Coombs test.

Patients with a history of allergy to this product or cephalosporin antibiotics are contraindicated.

Precautions for children: The safety and efficacy of cefixime for children under 6 months of age have not been determined. Precautions for pregnancy and lactation: Reproductive studies in mice and rats at doses up to 400 times the human dose showed no evidence of damage to fetal mice. The safety of the drug during pregnancy has not been determined, so when using the drug for pregnant women or women who may become pregnant, the pros and cons must be weighed, and the drug can only be used when the benefits outweigh the cons. The effect of cefixime on delivery has not been studied, and it can only be used when it is clearly needed. It is unclear whether cefixime is excreted in human milk. When using this product, consider suspending breastfeeding. Precautions for the elderly: 1. The peak blood concentration and AUC of this product in the elderly can be 26% and 20% higher than those in young people, respectively, and the elderly can use this product. 2. Patients with renal insufficiency should adjust the dosage, and patients with a creatinine clearance of ge; 60ml/min can use it according to the normal dose and course of treatment. Patients with a creatinine clearance of 21~60ml/min or hemodialysis can be given at 75% of the standard dose (standard dosing interval). Patients with creatinine clearance of 20 ml/min or long-term bedridden peritoneal dialysis can be given half the standard dose (standard dosing interval).

1. This product is incompatible with the following drugs and cannot be infused in the same bottle: amikacin sulfate, kanamycin sulfate, chlortetracycline hydrochloride, oxytetracycline hydrochloride, tetracycline hydrochloride, erythromycin gluconate, polymyxin B sulfate, colistin sodium methanesulfonate, pentobarbital, calcium gluconate, calcium gluconate. 2. This product can enhance the antibacterial effect in vitro when used in combination with gentamicin or amikacin. 3. This product may increase nephrotoxicity when used in combination with strong diuretics, and may increase the nephrotoxicity of the latter when used in combination with aminoglycoside antibiotics. 4. Probenecid can increase the blood concentration of this product and prolong its blood half-life.

Sealed, stored in a cool and dry place, valid for 2 years.

100mg

24 months

Tianjin Huajin Pharmaceutcial Co., Ltd.

• Founded in:

  2009-08-12

• Address:

  No. 28, Shuichanqian Street, Hebei District, Tianjin

• Tax NO.:

  911201051034716813

• Registered Funds:

  50.25 million yuan

• Website:

  Log in to view

• Email:

  Log in to view